Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · Annals of Oncology · 2016 · 2.6K citations · Full text

Medicine, Oncology, Surgery +14

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman et al. · Clinical Cancer Research · 2013 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17